Gilead Sciences, Inc. started off the year stating at the J.P. Morgan Healthcare Conference that oncology will account for one-third of its revenues by 2030. The firm’s 2021 sales demonstrate that it is largely dependent on infectious disease, but management used the 1 February earnings call to highlight some near-term catalysts in oncology that will help the firm with its diversification efforts.
“Our 2022 plans include a significant increase in clinical development studies across our novel oncology portfolio,” CEO Daniel O’Day told the fourth quarter/full year 2021 earnings call. The company’s full year sales beat guidance and quarterly sales beat consensus despite falling short of the comparable period of 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?